Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T17:57:47.626Z.
Calculation as of: 2026-10-06T17:57:47.626Z.
Quote observation: 2026-10-06T17:55:08.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 23d17170dcd90d56222e16e6e1c46ca5d6e49f0f5e08d353dc7d5f06f7b1586d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$10.01B
EBITDA Yield
3.58%
TTM Avg
4.57%
3Y Avg
5.12%
5Y Avg
4.77%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Vaxcyte, Inc. (PCVX) | $9.34B | N/A | N/A | N/A | N/A |
| Insulet Corp. (PODD)vs › | $9.38B | 6.35% | 4.06% | 2.63% | 1.89% |
| Bruker Corporation (BRKR)vs › | $9.29B | 3.24% | 4.44% | 4.68% | 4.77% |
| Krystal Biotech, Inc. (KRYS)vs › | $9.61B | 2.22% | 2.23% | 2.14% | 2.14% |
| Henry Schein, Inc. (HSIC)vs › | $9.65B | 8.17% | 8.49% | 8.43% | 8.63% |
| Axsome Therapeutics, Inc. (AXSM)vs › | $9.00B | N/A | N/A | N/A | N/A |
| Bruker Corporation (BRKRP)vs › | $8.98B | 3.33% | 0.70% | 0.72% | 0.72% |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $10.01B | 3.58% | 4.57% | 5.12% | 4.77% |
| Repligen Corporation (RGEN)vs › | $10.01B | 1.47% | 1.65% | 1.35% | 1.70% |
| Protagonist Therapeutics, Inc. (PTGX)vs › | $8.77B | 0.72% | 0.48% | 4.02% | 4.02% |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
